Regeneron Facing Headwinds After 'Underwhelming' Itepekimab Results, Truist Says
Published on 30/05/2025 at 15:10

Published on 30/05/2025 at 15:10
Real-time
Other stock markets
|
||
83.95 EUR | +1.51% |
Select your edition
All financial news and data tailored to specific country editions